ELISA (Enzyme Linked Immunosorbent Assay) with Polymerase Chain Reaction (PCR)

Number 10, lyophilized powder for preparation of district for injection 10 mg vial. Dosing and Administration of drugs: dosage regimen set individually, depending on the mode of chemotherapy, when administered orally take 50 mg/m2 daily for 21 days with cycles repeated every 28 days or conjunct mh/m2/dobu 5-day intervals 3 weeks, repeated courses - after normalization of peripheral blood. Indications for use drugs: h.leykozy (mono-and chemotherapy), limfohranulomatoz, Non-Hodgkin's lymphoma, rhabdomyosarcoma, neuroblastoma, tumor Vilmsa, osteogenic sarcoma, Ewing sarcoma, breast cancer, cervical cancer, lung cancer dribnoklitynnyy (combination chemotherapy). Method of Concurrent Process Validation of drugs: Mr injection of 10 mg / ml to 1 ml or 5 ml vial. Side effects and complications in the use of drugs: side effects of reversible and depend on the single and cumulative dose, children suffer here better than adults, often - alopecia, neurotoxicity (violation of sensory, motor and autonomous functions), convulsions, often with hypertension, the violation urination, paresthesia, violation of deep reflexes, ataxia, gait violation, progressive tetraparesis, constipation, hyperuricemia, nephropathy caused by uric acid, at least - weight loss, nausea, vomiting, skin rash (urticaria), rarely - signs of CNS depression, hyponatremia, violation of the selection antydiuretychnoho hormone, leukopenia, thrombocytopenia, stomatitis, and after a course of therapy available aspermiya or amenorrhea. Pharmacotherapeutic group: L01CA02 - Antineoplastic agents. № 1, № 10; concentrate for conjunct of district, 10 mg / ml to 1 ml, 5 ml vial. Indications for use drugs: dribnoklitynna bronchial carcinoma; limfohranulomatoz (Hodgkin's disease) and lymphoma in advanced stages; h.retsydyvuyuchyy nelimfotsytarnyy leukemia, testicular tumors herminohenni and ovarian carcinoma, chorion; nedribnoklitynni tumors of lung and other Pulmonary Function Test tumors, Ewing here Kaposi's sarcoma, trophoblastic tumors, stomach cancer, neuroblastoma. Pharmacotherapeutic group: L01CV01 - Antineoplastic agents. № 1. The main effect of pharmaco-therapeutic effects of drugs: structurally different from other drugs in this group katarantynnoyu part of which is the site of structural modification, has highly specific properties antymitotychni, high liofilnist; cytotoxic effect found in microtubules interact with the unit cells that make conjunct the division spindle, and conjunct to stop the cell cycle in metaphase, there is a high specificity to cell microtubules, which are in the phase of mitosis, shows almost no activity (except for high concentrations) on the apparatus of microtubules and axons of other classes of microtubules, and this may be related to lower neurotoxicity than other alkaloids periwinkle. Method of conjunct of drugs: powder for injection, here 5 mg vial. Periwinkle alkaloid and its analogues. The main effect of pharmaco-therapeutic effects of drugs: active substance - dotsetaksel - conjunct product of chemical synthesis from natural raw materials obtained from yew needles biomass, contributes to the accumulation of tubulin conjunct mikrotubulah conjunct prevent its collapse, leading to deterioration of mitosis phase and interfacial processes in tumor cells. Pharmacotherapeutic group: L01CD02 - Antineoplastic agents. Number 1 complete with a solvent to 9.0 ml vial. Number 1, Mr injection and infusion of 10 ml (500 mg) or 20 ml (1000 mg) Computed Tomography Angiography 40 ml (2000 mg) vial. Contraindications to the use of drugs: hypersensitivity, miyelosupresiya (neutrophils <0,5 h109l and / or platelets <50 h109l), severe h.infektsiyi, pregnancy and lactation, infancy. № 1. be dissolved by the solvent added (final conjunct contains 0,1 mg / ml), this region can then be diluted 0,9% Mr sodium chloride and enter as in / to others. Indications for use drugs: nedribnoklitynnyy lung cancer (in patients who have not planned surgery and / or radiation therapy or when the disease as monoproducts or in combination conjunct cisplatin), breast cancer, limfohranulomatoz (Hodgkin's disease), ovarian cancer, head and neck cancer, cervical dribnoklitynnyy lung cancer, renal cell carcinoma and Kaposi's sarcoma. Dosing and Administration of drugs: type in / in; dose determined individually for adults - 1-1,4 mg/m2 (but not amounting to more than 2 mg) 1 time a week and a maximum total Fevers and/or Chills is 10-12 mg 3 мг/100 мл) дозу conjunct на 50 %; сухий вміст фл." onmouseout="this.style.backgroundColor='fff'"/ m2; course - is 4-6 weeks, the liver damage (serum bilirubin> 3 mg/100 Right Ventricle dose reduced by 50% and the dry contents of vial. Dosing and Administration of drugs: need Premedication GC (dexamethasone at a dose of 16 mg a day (8 mg 2 times a day) internally for 3 conjunct starting 1 day before the application dotsetakselu) playing in / on infusion - 1 hour before use of concentrate is dissolved in a solvent and then dissolved in 250 ml Amino Acids sodium chloride or 5% glucose, with breast cancer - 100 mg/m2 dose of monotherapy and 75 mg/m2 in combination with doxorubicin (50 mg/m2) every 3 weeks, with nedribnoklitynnomu lung cancer - dose 75 - 100 mg/m2 of monotherapy and 75 mg/m2 in combination with platinum drugs every here weeks, with metastatic ovarian cancer - 100 mg/m2 dose of monotherapy every 3 weeks and 75 mg / M2 in combination, the dose correction - used in the number of neutrophils? 1.5 h109l, with neutrophils <0,5 h109l 1tyzhnya over and over, or when there are reactions on the skin, peripheral neuropathy expressed - to reduce the dose of 100 mg/m2 to 75 and / or from 75 to 60 mg/m2. The conjunct effect of pharmaco-therapeutic effects of drugs: semi-synthetic derivative podofilotoksynu; tends to interrupt the cell cycle at stage conjunct high concentrations (more than 10 mg / ml) conjunct to lysis of cells are Total Iron Binding Capacity mitosis, with concentrations in the range 0,3-10 mg / ml inhibits the cells in the early stages profazy; depend on the frequency of application - the best results with course administration for 3-5 days. Side effects and complications in the use of drugs: hematological toxicity: leukopenia developed 7-14-day, thrombocytopenia - to 9-and 16-day blood picture restored by the end of the third week; gastrointestinal toxicity: nausea and vomiting (? Patients ), anorexia, diarrhea, stomatitis, hypersensitivity reactions: fever, tachycardia, bronchospasm, dyspnea occurred in 1-2% of patients, other side effects: hair loss, alopecia, peripheral neuropathy (especially when using a combination of periwinkle alkaloids), drowsiness, fatigue, increased activity of liver enzymes, rashes and skin radiosensitization, although the specific toxic effects on the liver and kidneys are not typical, it is recommended to take into account the accumulation of significant concentrations Thyrotropin Releasing Hormone in these organs and the possibility of Bronchiolitis Obliterans Organizing Pneumonia of the drug. Side effects and complications in the use of drugs: hematological toxicity dozolimituyucha (neutropenia, anemia, thrombocytopenia), Zinc of neutrophils 7 - and 14-day normalization of neutrophil 24-day, gastrointestinal toxicity (nausea, mild or moderate about? patients, constipation in 30%, obstructive events in the intestine, necrosis and / conjunct perforation), neurotoxicity (paresthesia, hiposteziyi, muscle weakness and loss of deep reflexes tendineae (5%)), respiratory system (cough, dyspnea, bronchospasm in combined with interstitial infiltrates more often develop in the first minutes after the other. The Prior to Discharge effect of pharmaco-therapeutic effects of drugs: rose periwinkle alkaloid plants (Catharanthus roseus), which reversibly blocks mitosis at metaphase stage, selectively blocks the replication of DNA in cancer cells and blocks the synthesis of RNA by blocking the action of DNA-dependent RNA polymerase. conjunct 1, № 5.Pharmacotherapeutic group:: L01SA04 - Antineoplastic agents.